Alejandro Contreras
Overview
Explore the profile of Alejandro Contreras including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1872
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ye Q, Law T, Klippel D, Albarracin C, Chen H, Contreras A, et al.
Mod Pathol
. 2025 Jan;
38(4):100708.
PMID: 39788205
Different digital modalities are currently available for frozen section (FS) evaluation in surgical pathology practice. However, there are limited studies that demonstrate the potential of whole-slide imaging (WSI) as a...
2.
Snoddy E, Tang T, Fowlkes N, Huynh T, Brewer Savannah K, Contreras A, et al.
medRxiv
. 2025 Jan;
PMID: 39763534
Background: Hematoxylin and eosin (H&E) staining is widely considered to be the gold-standard diagnostic tool for histopathology evaluation. However, the fatty nature of some tissue types, such as breast tissue,...
3.
Shaitelman S, Le-Petross H, Raso M, Swanson D, Schalck A, Contreras A, et al.
Int J Radiat Oncol Biol Phys
. 2024 Aug;
121(1):90-96.
PMID: 39147206
Purpose: Radiation therapy is an underinvestigated tool for priming the immune system in intact human breast cancers. We sought here to investigate if a preoperative radiation therapy boost delivered was...
4.
Peirone A, Contreras A, Guevara A, Allub A, Bueno N, Banille E, et al.
World J Pediatr Congenit Heart Surg
. 2022 Oct;
14(1):90-92.
PMID: 36262106
Ruptured sinus of Valsalva aneurysm is rare, although if left untreated, potentially fatal disease. Surgical approach has been the main treatment in most series; nevertheless, percutaneous closure has been described...
5.
Thomas P, Patel A, Lee J, Liu D, Hernandez M, Muzzio M, et al.
Cancer Prev Res (Phila)
. 2022 Oct;
16(1):47-55.
PMID: 36228112
Bexarotene is a rexinoid that has been shown to prevent mammary tumors in mouse models but oral dosing has toxicities. This phase I study evaluates topical bexarotene, as a potential...
6.
Mazumdar A, Tahaney W, Hill J, Zhang Y, Ramachandran S, Kawedia J, et al.
Cancer Prev Res (Phila)
. 2022 Aug;
15(12):791-802.
PMID: 35981902
Our results show that everolimus delays mammary tumor formation in multiple mouse models, suggesting that mTOR inhibitors will be useful for the prevention of ER-negative and triple-negative breast cancer in...
7.
Kumar T, Hobbs E, Yang F, Chang J, Contreras A, Parra Cuentas E, et al.
Clin Cancer Res
. 2022 Jun;
28(17):3669-3676.
PMID: 35736816
Purpose: The immunological profile of early-stage breast cancer treated with neoadjuvant PARP inhibitors has not been described. The aim of this study was to delineate the changes in the tumor...
8.
Liu X, Ge Z, Yang F, Contreras A, Lee S, White J, et al.
NPJ Breast Cancer
. 2022 May;
8(1):64.
PMID: 35538088
Germline mutations in BRCA1 or BRCA2 exist in ~2-7% of breast cancer patients, which has led to the approval of PARP inhibitors in the advanced setting. We have previously reported...
9.
Goodbrake C, Li D, Aghakhani H, Contreras A, Reece G, Markey M, et al.
Ann Biomed Eng
. 2022 Mar;
50(5):601-613.
PMID: 35316441
As the human breast undergoes complex, large-scale, fully three dimensional deformations in vivo, three-dimensional (3D) characterization of its mechanical behavior is fundamental to its diagnosis, treatment, and surgical modifications. Its...
10.
Sevelius J, Glidden D, Deutsch M, Welborn L, Contreras A, Salinas A, et al.
J Acquir Immune Defic Syndr
. 2021 Nov;
88(S1):S27-S38.
PMID: 34757990
Background: TRIUMPH (Trans Research-Informed communities United in Mobilization for the Prevention of HIV) was a community-led, transgender-specific pre-exposure prophylaxis (PrEP) demonstration project at 2 community-based clinical sites in California. TRIUMPH...